Institut de Recherches Internationales Servier
Quick facts
Phase 3 pipeline
- AG-120 · Oncology
AG-120 is an isocitrate dehydrogenase 1 (IDH1) inhibitor that blocks the production of the oncometabolite 2-hydroxyglutarate in IDH1-mutant cancers. - Bevacizumab control · Oncology
Bevacizumab is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF) to inhibit tumor angiogenesis and reduce blood supply to cancer cells. - Bevacizumab experimental · Oncology
Bevacizumab is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF), inhibiting tumor angiogenesis and reducing blood supply to cancer cells. - Fixed [Per/Ind/Aml] · Cardiovascular
A fixed-dose combination of perindopril (ACE inhibitor), indapamide (thiazide-like diuretic), and amlodipine (calcium channel blocker) that reduces blood pressure through multiple complementary pathways. - Free [Per/Ind + Aml] · Cardiovascular
A fixed-dose combination of perindopril (ACE inhibitor) and amlodipine (calcium channel blocker) that reduces blood pressure through dual vasodilation and renin-angiotensin system inhibition. - Temozolomide (TMZ) · Oncology
Temozolomide is an alkylating agent that methylates DNA at the O6 position of guanine, causing DNA strand breaks and cell death.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: